A biphasic calcium phosphate coating for potential drug delivery affects early osseointegration of titanium implants. (7th June 2016)

• Record Type: Journal Article
• Authors: Kämmerer, Till A.; Palarie, Victor; Schiegnitz, Eik; Topalo, Valentin; Schröter, Andrea; Al‐Nawas, Bilal; Kämmerer, Peer W.
• Is Part Of: Journal of oral pathology & medicine. Volume 46:Number 1(2017)
• Page Start: 61
• Page End: 66
• Publication Date: 2016-06-07
• Subjects: animal trial -- bone -- calcium phosphate -- drug delivery system -- endosseous implant; Dentistry -- Periodicals; Teeth -- Diseases -- Periodicals; 617
• DOI: 10.1111/jop.12464
• Languages: English
• ISSNs: 0904-2512

Abstract

Abstract : Background: Calcium phosphate (CaP) surface coatings may accelerate osseointegration and serve as a drug delivery system for mineral‐binding biomolecules. In a pilot study, the impact of a commercially available, thin CaP coating on early osseous bone remodeling was compared with a modern, subtractive‐treated rough surface (SLA‐like) in an animal trial. Methods: In 16 rabbits, 32 endosseous implants (CaP; n = 16, SLA‐like; n = 16) were bilaterally inserted in the proximal tibia after randomization. After 2 and 4 weeks, bone‐implant contact (BIC;%) in the cortical (cBIC) and the trabecular bone (sBIC) as well as volume of bone within the screw thread with the highest amount of new‐formed bone (area;%) were analyzed. Results: After 2 weeks, cBIC was significantly higher for CaP when compared with SLA‐like (58 ± 7% versus 40.4 ± 18%; P = 0.021). sBIC for CaP was 14.7 ± 8% and for SLA‐like 7.2 ± 7.8% ( P = 0.081). For area, the mean volumes were 82.8 ± 10.8% for CaP and 73.6 ± 22% for SLA‐like ( P = 0.311). After 4 weeks, cBIC was 42.9 ± 13% for the CaP and 46.5 ± 29.1% for the SLA‐like group ( P = 0.775). An sBIC of 6.9 ± 9.3% was calculated for CaP and of 12.3 ± 4.8% for SLA‐like ( P = 0.202). The values for area were 62.3 ± 24.1% for CaP and 50.1 ± 25.9% for SLA‐like ( P = 0.379). Conclusions: The CaP coating has putative additional advantages in the early osseoconduction phases. It seems suitable for a feasible and clinical applicable bioactivation.